Logo image
Sign in
Time from completion of chemotherapy to disease progression as a clinically relevant endpoint in women with epithelial ovarian, primary peritoneal, and fallopian tube cancers treated with and without bevacizumab
Journal article   Peer reviewed

Time from completion of chemotherapy to disease progression as a clinically relevant endpoint in women with epithelial ovarian, primary peritoneal, and fallopian tube cancers treated with and without bevacizumab

L. Randall, R. Burger, H. Nguyen, G. Kong, M. Bookman, G. Fleming, B. Monk, R. Mannel and M. Birrer
Gynecologic oncology, Vol.130(1), pp.e120-e120
07/2013

Metrics

4 Record Views

Details